Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16985244 | 0.83 | MKNK1 (0.38) | NPC1HPGDRAB9ASMN1; SMN2CCR2 | |
| SCHEMBL8799954 | 0.79 | CA2 (0.39) | NPC1HPGDRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8799649 | 0.74 | AHR (0.41) | NPC1RAB9ASMN1; SMN2KMT2ACA2 | |
| SCHEMBL8797911 | 0.72 | CA2 (0.54) | CCR2CA2ARF2RL3PKM | |
| SCHEMBL720789 | 0.71 | CA2 (0.67) | HPGDSMN1; SMN2CCR2CA2CA12 | |
| SCHEMBL9063028 | 0.71 | CA2 (0.67) | HPGDSMN1; SMN2CCR2CA2CA12 | |
| SCHEMBL2097841 | 0.68 | NPC1 (0.39) | NPC1HPGDRAB9ASMN1; SMN2AR | |
| SCHEMBL12728518 | 0.68 | CYP1A1 (0.40) | NPC1HPGDRAB9ASMN1; SMN2AR | |
| SCHEMBL17193877 | 0.68 | NPC1 (0.36) | NPC1HPGDRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16686379 | 0.68 | CYP2A6 (0.52) | NPC1HPGDRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602807-B | Heterocyclic sulfonamide derivatives and drugs containing the same | EA制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3412664-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | EA PHARMA CO LTD (JP) | 2022-03-30 | — | — | EP | disclosed |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | EA PHARMA CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-10584116-B2 | Heterocyclic sulfonamide derivative and medicine containing same | EA PHARMA CO., LTD. (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20190023699-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023699-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3412664-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | EA Pharma Co., Ltd. (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023699-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | TRPA1, TRPV1, TRPV2 | NPC1 676/4885HPGD 769/4885RAB9A 3409/4885 |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | NPC1 705/4885HPGD 853/4885RAB9A 3760/4885 |
| US-10626112-B2 | Heterocyclic sulfonamide derivative and medicine comprising same | TRPA1, TRPV1, TRPV2 | NPC1 705/4885HPGD 853/4885RAB9A 3760/4885 |
| US-10584116-B2 | Heterocyclic sulfonamide derivative and medicine containing same | TRPA1, TRPV1, TRPV2 | NPC1 676/4885HPGD 769/4885RAB9A 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.